PDCD1 and hepatocellular carcinoma: According to a meta-analysis, the combination of HAIC and anti-PD-1/anti-PD-L1 was associated with an increased incidence and severity of adverse events, but also improved treatment outcomes and prognosis for patients with unresectable HCC compared to the combination of anti-angiogenic agents and anti-PD-1/anti-PD-L1 [147].